Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Immunoglobulin A nephropathy (IgAN) is the most common form of primary glomerulonephritis that can lead to kidney failure (KF). The objective of the literature review was to collate and summarize clinical and humanistic burden associated with IgAN.
A comprehensive literature search was performed in September 2024 in Embase and MEDLINE through the Embase platform for relevant English-language studies.
A total of 108 studies, 66 from Asia, 22 from Europe, 6 from the US, and 14 from other regions were included. Study sample sizes varied from 8 to 11,963. The mean patient ages ranged from 25.2 to 51.6 years. Hypertension and diabetes were the most frequently reported comorbidities. Persistent proteinuria was noted despite treatment with renin–angiotensin–aldosterone system inhibitors, corticosteroids and non-steroidal immunosuppressants. The mean proteinuria at follow-up ranged from 0.3 g/day (Japan, mean study follow-up of 60 months) to 6 g/day (Italy, mean study follow-up of 67 months). The proportion of patients with >=50% decline in eGFR ranged from 0.6% (Sweden) to 87% (South Korea), at median follow-up of approximately 6 years. The proportion of patients experiencing KF at median study follow up of <=5 years ranged from 2% in China to 31.9% in Canada. Various histopathological and clinical factors were associated with progression to KF. Histopathological presentations of tubular atrophy, interstitial fibrosis and high histopathological disease grade (III/IV) were associated with progression to KF (P<0.01 each). Clinical and demographic factors such as hypertension, RAASI treatment, eGFR (baseline ≥90 mL/min, per 30-mL/min decrease), proteinuria (baseline ≤0.5 g/day, per 0.5-g/day increase), advanced age and Pacific Asian population were associated with progression to KF (P<0.001 each). In a Swedish study, 40.7% of patients required renal replacement therapy after median follow-up of 65.9 months. In the UK study, 24% of adults required dialysis after a mean follow-up of 92.4 months. Renal transplantation rates were as high as 53.2% (USA, mean study follow-up 45.8 months). The mortality rate at median study follow-up of less <=5 years ranged from 0.5% in China to 21.8 in the US.
The impact of IgAN and its symptoms on patients' quality of life (QoL) was assessed in a survey using the EuroQol Visual Analogue Scale (EQ VAS) (scale range 0 [worst imaginable health] to 100 [best imaginable health]). Patients with higher proteinuria (>=1 g/day) had a mean score of 67.5, while those with lower proteinuria (<1 g/day) had a mean score of 75.5. Similarly, patients with lower eGFR (<45 mL/min/1.73 m²) reported a mean EQ-VAS score of 60, compared to a score of 73.8 among those with higher eGFR (>=45 mL/min/1.73 m²), indicating an association between deteriorating kidney function (higher proteinuria and lower eGFR) and QoL.
Evidence indicates that IgAN is associated with significant clinical and humanistic burden. The high clinical burden and low QoL in IgAN patients indicates an unmet need for interventions that lower or arrest the disease progression and prevent KF.
